Clinical Trial Update: Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) [Phase 3]

View source ↗

Summary

Phase 3 extension study comparing safety and tolerability of vildagliptin versus sitagliptin in type 2 diabetes patients with severe renal insufficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Insufficiency
• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (sitagliptin)
• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency | Phase 3 | Status: COMPLETED